Nov 15, 2019 7:30am EST Rigel Receives Positive CHMP Opinion for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe
Nov 07, 2019 7:30am EST Rigel Announces Upcoming Data Presentations at the 61st ASH Annual Meeting & Exposition
Oct 29, 2019 7:30am EDT Rigel Announces Conference Call and Webcast to Report Third Quarter 2019 Financial Results
Oct 23, 2019 7:30am EDT Rigel Pharmaceuticals Provides Business Update Prior to Investor & Analyst Call
Oct 18, 2019 7:30am EDT Rigel Receives Positive Trend Vote from CHMP for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe
Sep 23, 2019 7:30am EDT Rigel's fostamatinib Enters Phase 3 Clinical Trial in Japan with Kissei Pharmaceuticals for the Treatment of Chronic Immune Thrombocytopenia
